What type of study is this?

This is a In Vitro Study study.

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa

View Full Paper

Ask AI

Bookmark

Pharmacometric analyses adjust dosing regimens for renal function in Pseudomonas aeruginosa, highlighting safe therapeutic drug monitoring options.

Aminoglycoside dosing regimens adjusted for renal function improved therapeutic outcomes and safety monitoring.
Recommended breakpoints for susceptibility and resistance identified were ≤2 and ≥8 µg/mL for amikacin, respectively.
Assessment using pharmacokinetic–pharmacodynamic target attainment analyses validated dosing strategies for Enterobacterales.
Findings support optimal use of aminoglycosides through evidence-based recommendations for dosing adjustments.

A 2025 study studied this question.

View Full Paper

Ask AI

Bookmark

Pharmacometric analyses adjust dosing regimens for renal function in Pseudomonas aeruginosa, highlighting safe therapeutic drug monitoring options.